This antibody recognises human major histocompatibility complex (MHC) class I molecules.
| Institute |
|---|
| University of Birmingham |
| SKU: | 151493 |
|---|---|
| Product description: | This antibody recognises human major histocompatibility complex (MHC) class I molecules. MHC Class I is a heterodimeric protein, consisting of a heavy and light chain. Class I molecules are expressed by most haematopoietic cells and play a central role in the immune response. |
| Conjugation: | Unconjugated |
| Isotype: | IgG1 |
| Myeloma used: | P3/NS1/1-Ag4.1 |
| Cat. #: | 151493 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Immunology |
| Target: | Major Histocompatibility Complex I (HLA-ABC) |
| Reactivity: | Human |
| Clone: | BU8 |
| Host: | Mouse |
| Class: | Monoclonal |
| Target background: | This antibody recognises human major histocompatibility complex (MHC) class I molecules. MHC Class I is a heterodimeric protein, consisting of a heavy and light chain. Class I molecules are expressed by most haematopoietic cells and play a central role in the immune response. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 0.9-1.1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151021 | Anti-CyclinB1 [V152] |
Key Info
Anti-CyclinB1 [V152]
|
View Tool | |||||||||||||||||||
| 151023 | Anti-IL12 [1-1D5] |
Key Info
Anti-IL12 [1-1D5]
|
View Tool | |||||||||||||||||||
| 151027 | Anti-HSVICP8 [10A3] |
Key Info
Anti-HSVICP8 [10A3]
|
View Tool | |||||||||||||||||||
| 151033 | Anti-HSVUL42 [13C9] |
Key Info
Anti-HSVUL42 [13C9]
|
View Tool | |||||||||||||||||||
| 151037 | Anti-Cdk1 [17 (A17)] |
Key Info
Anti-Cdk1 [17 (A17)]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.